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650Objective: The impact of Society of Thoracic Surgeons predicted mortality risk score on resource use has not
been previously studied. We hypothesize that increasing Society of Thoracic Surgeons risk scores in patients
undergoing aortic valve replacement are associated with greater hospital charges.
Methods: Clinical and financial data for patients undergoing aortic valve replacement at The Johns Hopkins
Hospital over a 10-year period (January 2000 to December 2009) were reviewed. The current Society of Tho-
racic Surgeons formula (v2.61) for in-hospital mortality was used for all patients. After stratification into risk
quartiles, index admission hospital charges were compared across risk strata with rank-sum and Kruskal–Wallis
tests. Linear regression and Spearman’s coefficient assessed correlation and goodness of fit. Multivariable anal-
ysis assessed relative contributions of individual variables on overall charges.
Results: A total of 553 patients underwent aortic valve replacement during the study period. Average predicted
mortality was 2.9% (3.4) and actual mortality was 3.4% for aortic valve replacement. Median charges were
greater in the upper quartile of patients undergoing aortic valve replacement (quartiles 1–3, $39,949 [interquar-
tile range, 32,708–51,323] vs quartile 4, $62,301 [interquartile range, 45,952–97,103], P<.01]. On univariate
linear regression, there was a positive correlation between Society of Thoracic Surgeons risk score and log-
transformed charges (coefficient, 0.06; 95% confidence interval, 0.05–0.07; P<.01). Spearman’s correlation
R-value was 0.51. This positive correlation persisted in risk-adjusted multivariable linear regression. Each
1% increase in Society of Thoracic Surgeons risk score was associated with an added $3000 in hospital charges.
Conclusions: This is the first study to show that increasing Society of Thoracic Surgeons risk score predicts
greater charges after aortic valve replacement. As competing therapies, such as percutaneous valve replacement,
emerge to treat high-risk patients, these results serve as a benchmark to compare resource use. (J Thorac
Cardiovasc Surg 2011;142:650-5)The grim natural course of untreated symptomatic severe
aortic stenosis (AS) was first shown by Ross and Braunwald
in 19681 and reaffirmed by the medically managed cohort of
patients in the recent publication of the PARTNER trial.2 In
the PARTNER study, patients receiving optimal medical
treatment experienced 50% 1-year mortality.2 In light of
these sobering statistics, the effectiveness of aortic valve re-
placement (AVR) for severe AS cannot be overstated. Pa-
tients across all age ranges not only derive a dramatic
survival advantage but also enjoy greater quality of life,
whether undergoing standard sternotomy or a less invasive
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The Journal of Thoracic and Cardiovascular SurgIn 2002, the first successful percutaneous AVR was per-
formed, avoiding the need formedian sternotomy.7Retrospec-
tive results with this transcatheter aortic-valve implantation
(TAVI) approach have subsequently been widely reported.8-12
Thefirst randomized, prospective trial in theUnitedStateswas
recently published, which revealed a significant survival ad-
vantage forTAVIover bestmedicalmanagement in inoperable
patients with severe AS.2 As this new technology gains wide-
spread application, it will be incumbent on the cardiovascular
community to give consideration to cost-effectivenesswith re-
gard to this new therapy. The Society of Thoracic Surgeons
(STS) risk prediction models enable clinicians to compare
groups of patients on the basis of similar preoperative risk pro-
files.13 In the PARTNER study, STS risk scores were used to
define the eligible patient population. To serve as a benchmark
for cost-effectiveness comparisons, the hypothesis that in-
creasing STS risk scores in patients undergoingAVR are asso-
ciatedwith greater hospital charges and resource consumption
was tested.MATERIALS AND METHODS
Patient Data
This was a retrospective review of the cardiac surgery database, which is
managed by a dedicated data center team within the Division of Cardiacery c September 2011
Abbreviations and Acronyms
AS ¼ aortic stenosis
AVR ¼ aortic valve replacement
CI ¼ confidence interval
CVA ¼ cerebrovascular accident
HSCRC ¼ Health Services Cost Review
Commission
IQR ¼ interquartile range
RRT ¼ renal replacement therapy
STS ¼ Society of Thoracic Surgeons
TAVI ¼ transcatheter aortic-valve implantation
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MSurgery at The Johns Hopkins Hospital. All patients undergoing AVR with
a tissue or mechanical prosthesis at The Johns Hopkins Hospital from Jan-
uary 2000 to December 2009 were included. Patients with prior sternotomy
were included. Those patients who underwent other concomitant cardiac
surgical procedures (coronary artery bypass, ascending aortic aneurysm re-
pair, atrial septal defect repair, radiofrequency ablation) and pediatric pa-
tients (<18 years) were excluded. There were 553 patients with isolated
AVR who comprised the cohort for this analysis.
All charts of these patients were available for review, and after institu-
tional review board approval all relevant clinical information was extracted
from the institutional cardiac surgery database and the electronicmedical re-
cord as necessary. Demographic and clinical variables included age, gender,
race, cardiovascular comorbidities, smoking history, and ejection fraction.
STS risk score for operative mortality was calculated according to version
6.21, which was introduced in 2008. For patients before 2008, all necessary
data were used to extrapolate a risk score according to version 6.21.
Outcomes
Postoperative data included operative mortality, length of stay, in-
hospital drug-treated infections, postoperative cerebrovascular accidents
(CVAs), renal replacement therapy (RRT), and deep sternal infections.
These complications were reviewed from both data submitted to the STS
database and independent review of the electronic medical record. Survival
status was supplemented using the Social Security Death Index.
Charges Data
Hospital charges are obtained through the hospital billing department as
reported to the Maryland State authorities and represent total hospital
charges for the index admission only. These charges include those incurred
during the operation and for all aspects of postoperative care. The state of
Maryland Health Services Cost Review Commission (HSCRC) is the only
system of its kind in the United States, and this commission minimizes
cost-shifting by establishing payment rates for all insurers within the state
of Maryland.
Charges data are divided into the following categories: routine charges,
operating room facility use, operating room supply use, pharmacy charges,
laboratory charges, radiology charges, physical therapy charges, and other
charges. For any patient hospitalized before AVR, index admission charges
begin with the date of the operation. All financial information was inflation-
adjusted according to the US Department of Labor Consumer Price Index
in US dollars for the year 2009.
Statistical Analysis
Patients were stratified into quartiles according to STS risk scores. Dif-
ferences between patients in STS Q1–3 and STS Q4 were compared using
the 2-tailed Student t test for normally distributed continuous variables.The Journal of Thoracic and CaChi-square analysis was used for categoric variables. For nonparametric
continuous data, Wilcoxon rank-sum test was used. To confirm nonpara-
metric distributions, the data were visually inspected in graphic form and
checked for skewness. TheWilcoxon rank-sum test compared index admis-
sion charges data between Q1–3 and Q4. To determine differences among
the 4 individual quartiles, the Kruskal–Wallis nonparametric analysis of
variance was used. Post hoc multiple pairwise testing analyzed individual
differences among the 4 quartiles, with Bonferroni-adjusted P values.
To test for an STS risk score that would predict increased charges, re-
ceiver operating characteristic curves were used. The outcome measure
for high charges was defined as the upper 5% of median index admission
charges. An area under the curve greater than 0.7 was deemed significant.
A histogram of absolute charges revealed a non-normal distribution. Af-
ter logarithmic transformation of charges data, visual inspection revealed
amore normal distribution. To further confirm that no assumptions of linear
regression had been violated, residual values of the regression model were
plotted against fitted values and demonstrated equal variance across the
spectrum of STS risk scores. Univariate linear regression assessed the cor-
relation between continuous STS risk score and log index hospitalization
charges. A separate univariate linear regression was performed with STS
risk score greater than or less than 10% as a binary independent variable.
Multivariable linear regression determined the relative contributions of in-
dividual variables toward index admission charges. In addition to variables
associated with charges on exploratory univariate analysis (P<.1), those
with biological plausibility were incorporated in a forward and backward
stepwise fashion into the multivariable linear regression model. The likeli-
hood ratio test and Akaike’s information criterion in a nested model ap-
proach were used to identify which covariates increased the explanatory
power of the model. The final model incorporated the following covariates:
STS risk score, age, ejection fraction, preoperative CVA, chronic kidney
dysfunction, chronic obstructive pulmonary disease, diabetes mellitus,
postoperative major complication (composite of CVA, RRT, or pneumo-
nia), and operative mortality.
Continuous variables are presented with the mean standard deviation.
Categoric variables are shown in whole numbers and percentages. All ac-
tual charges data are presented in median and interquartile range (IQR).
Regression coefficients are presented with 95% confidence intervals
(CIs). Actual P values are reported except when less than .001. Analysis
was performed using Stata statistical software, version 9.2 (StataCorp,
College Station, Tex).RESULTS
Cohort Statistics
From January 2000 to December 2009, 553 patients
underwent isolated AVR at our institution and comprise
the cohort for this analysis. The mean age was 67.0 14.1
years, and 40% were female (n ¼ 222). The race distribu-
tion of the cohort was Caucasian (81%; n ¼ 447), African
American (14%; n ¼ 76), Hispanic (0.5%; n ¼ 2), and
other (4.5%; n ¼ 26). Forty-three patients (8%) reported
a history of smoking. Throughout the study period, the
number of yearly adult isolated AVR procedures remained
relatively constant, ranging from 42 to 86 procedures
annually.Society of Thoracic Surgeons Risk Score Results
Mean STS risk score for the entire isolated AVR cohort
was 2.95 (3.4). Isolated AVR patients were grouped into
the following STS quartiles: Q1, 0.37 to 1.02, n ¼ 139;
Q2, 1.03 to 1.90, n ¼ 138; Q3, 1.91 to 3.44, n ¼ 138; Q4,rdiovascular Surgery c Volume 142, Number 3 651
TABLE 1. Baseline demographics and postoperative complications
Variables
Isolated AVR cohort
Q1–3
(N ¼ 415)
Q4
(N ¼ 138) P value
Mean age, y (SD) 63.8  13.2 76.5  12.3 <.001
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M3.49 to 30.29, n ¼ 138. Baseline demographic information
was compared between patients in Q1–3 and patients in Q4.
As expected, patients in Q4 were older with significantly
greater cardiovascular comorbidities. A history of smoking
was more common in patients in Q1–3.Male gender, no. (%) 274 (66%) 57 (41%) <.001
Caucasian race, no. (%) 343 (83%) 104 (75%) .3
Smoking history, no. (%) 38 (9%) 5 (4%) .04
Redo sternotomy, no. (%) 17 (4%) 9 (7%) .2
Cerebrovascular disease, no. (%) 28 (7%) 21 (15%) .002
Diabetes mellitus, no. (%) 83 (20%) 48 (35%) <.001
Hypertension, no. (%) 274 (66%) 114 (83%) <.001
Ejection fraction,% (SD) 54%  14 50%  15 .004
COPD, no. (%) 40 (10%) 36 (26%) <.001
Chronic kidney dysfunction,
no. (%)
23 (6%) 30 (22%) <.001
Outcomes
LOS, d (IQR) 7 (5-9) 10 (7-17) <.001
Duration of mechanical 9 (6-13) 17 (11-38) <.001Outcomes and Mortality Rates
By quartile, operative mortality rates for isolated AVR
were 1 (0.72%) Q1; 0 (0%) Q2; 2 (1.5%) Q3; and 16
(11.6%) Q4. Median hospital length of stay was longer in
Q4: 10 days (IQR, 7–17) versus 7 days (IQR, 5–9) for
Q1–3. Median duration of mechanical ventilation was
also greater in Q4: 17 hours (IQR, 11–37) compared with
9 hours (IQR, 5–13). Postoperative CVA, RRT, and pneu-
monia were also more common in Q4, although deep sternal
infection rates were equivalent. Demographic information
and postoperative complications for isolated AVR are
shown in Table 1.ventilation, h (IQR)
Pneumonia, no. (%) 8 (2.2%) 10 (7.2%) .01
CVA, no. (%) 5 (1.2%) 8 (5.8%) <.001
Renal replacement therapy,
no. (%)
9 (2.2%) 17 (12.3%) <.001
Deep sternal infection, no. (%) 2 (0.5%) 0 (0%) .4
AVR, Aortic valve replacement; SD, standard deviation; COPD, chronic obstructive
pulmonary disease; CVA, cerebrovascular accident; LOS, length of stay; IQR, inter-
quartile range.
FIGURE 1. Bar graph depicting median hospital charges by STS risk
quartile for isolated AVR. P<.001 by Kruskal–Wallis nonparametric anal-
ysis of variance and each individual quartile statistically different from
each other by pairwise comparison using Bonferroni corrected P values.
STS, Society of Thoracic Surgeons.Hospital Charges
For isolated AVR, median index admission charges were
higher in STS Q4: $62,301 (IQR, 45,952–97,103) for Q4
compared with $39,949 (IQR, 32,708–51,323) for Q1–3,
P< .001. Median index admission charges for individual
quartiles were Q1, $33,820 (IQR, 29,641–42,243); Q2,
$39,534 (IQR, 33,156–45,929); Q3, $49,571 (IQR,
38,710–62,554); and Q4, $62,301 (IQR, 45,952–97,103).
When examining each of the 4 STS quartiles by nonpara-
metric analysis of variance, there was an overall global dif-
ference in the group medians (P<.001). Multiple pairwise
comparisons with an adjusted significance level for the
Bonferroni correction revealed that all of the quartiles
were significantly different from each other for isolated
AVR (Figure 1).
For STS Q4 and Q1–3, the relative contributions of each
charge category to total index hospitalization charges for
isolated AVR patients are shown in Figure 2. Hospital
charges according to category were compared between
STS Q4 and Q1–3. When analyzing index admission
charges, the following categories were higher for STS Q4:
routine ward and intensive care unit care, operating room
supply charges, operating room facility charges, pharmacy
charges, laboratory services, radiology, and physical ther-
apy services.
Patients undergoing isolated AVR who died before dis-
charge had greater median charges than those who survived
to discharge (survivors: $42,917 [IQR, 33,829–59,222] vs
nonsurvivors: $136,769 [IQR, 65,855–316,461], P<.01).
Additional subanalysis was performed revealing patients
undergoing isolated AVR with STS risk score greater than
10% had significantly increased median hospital charges
(<10%: $42,785 [IQR, 33,820–59,391] vs >10%:
$88,241 [IQR, 58,518–129,693], P<.01).652 The Journal of Thoracic and Cardiovascular SurgArea under the receiver operating characteristic curve
was 0.72 (95% CI, 0.61–0.83). An STS risk score of
3.13% had the best discriminatory power for predicting
the upper 5% of index admission charges, with sensitivity
of 68% and specificity 73%.ery c September 2011
TABLE 2. Multivariable regression analysis
Variable Coefficient 95% CI P value
Age, y 0.01 0.002-0.004 .5
Diabetes mellitus 0.11 0.013-0.203 .03
COPD 0.13 0.011-0.248 .03
Preoperative CVA 0.19 0.049-0.331 .01
Chronic kidney dysfunction 0.12 0.032-0.277 .1
Ejection fraction,% 0.01 0.005-0.001 .1
Postoperative complication 0.67 0.529-0.826 <.01
In-hospital mortality 0.46 0.222-0.696 <.01
STS risk score 0.02 0.010-0.034 .01
CI, Confidence interval; COPD, chronic obstructive pulmonary disease; CVA, cere-
brovascular accident; STS, Society of Thoracic Surgeons.
FIGURE 2. Side-by-side pie charts showing breakdown of total hospital
charges by individual category for isolated AVR only. Chart on left corre-
sponds to STS risk score Q1–3 combined, and chart on right depicts STS
Q4. STS, Society of Thoracic Surgeons.
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Linear regression of charges data after logarithmic trans-
formation revealed a significant positive correlation be-
tween STS predicted risk score and index admission
charges (correlation coefficient, 0.06; 95% CI, 0.05–0.07;
P<.01), with a Spearman R-value of 0.51 (Figure 3). By
using the binary independent variable of STS risk score
greater than 10%, there was a positive correlation (coeffi-
cient, 0.64; 95%CI, 0.39–0.89; P<.01) with increased hos-
pital charges.
After adjustment with multivariable linear regression,
STS predicted risk score (coefficient, 0.04; 95% CI,
0.03–0.05; P< .01), diabetes mellitus (coefficient, 0.07;
95% CI, 0.01–0.14; P ¼ .04), a major postoperative com-
plication (coefficient, 0.45; 95% CI, 0.35–0.55; P<.01),
and in-hospital mortality (coefficient, 0.54; CI, 0.40–0.69;
P<.01) were all independently associated with increasedFIGURE 3. Results of univariate linear regression analysis for isolated
AVR with STS risk score as independent variable. Log charges used
as dependent variable (outcome measure). STS, Society of Thoracic
Surgeons.
The Journal of Thoracic and Ca
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Mhospital charges. The remaining variables did not reach sig-
nificant associations and are shown in Table 2.
DISCUSSION
This is the first study to evaluate the impact of high STS
predicted risk scores on hospital charges and resource use in
a cohort of patients undergoing AVR. Patients were strati-
fied into quartiles according to STS risk score to compare
index admission hospital charges. When examined against
other algorithms for mortality risk after isolated AVR, a re-
cent study demonstrated that the STS score most closely
correlates with outcomes.14 Consistent with our hypothesis,
a linear association was observed between STS risk scores
and hospital charges. Given the recent progress in percuta-
neous technology for AVR, the findings in this study estab-
lish a benchmark for future cost-effectiveness comparisons.
Charges Analysis
Because the focus of this study was to identify charges as-
sociated with delivering care during the operative procedure
and all subsequent hospital care, daily chargeswere obtained
to subtract all preoperative charges. Analysis in this fashion
permits a clear examination of the effect of STS risk score on
charges associated with operative and postoperative hospital
care only; however, it should be noted that patients with high
STS risk score may incur significant preoperative cost and
use significant hospital resources. Patients in STS Q4 had
higher median index admission charges than patients in
STSQ1–3 combined, supporting the hypothesis. In addition,
when comparing individual quartiles by analysis of variance,
pairwise comparisons revealed each successive quartile in-
crease was associated with greater charges. Median charges
for patients in the highest STS risk quartile were $30,000
more than median charges for patients in the lowest quartile.
This finding is further supported by the linear relationship ob-
served in the regression analysis (Figure 3). Univariate linear
regression determined that STS risk score had a positive cor-
relation with increasing index admission charges. Extrapo-
lating the regression coefficient from log charges to
absolute charges revealed that each 1% increase in STSrdiovascular Surgery c Volume 142, Number 3 653
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Mrisk scorewas associatedwith an additional $3000 in hospital
charges. Because of our rigorous regression methodologies,
we believe the linear regression results are robust and valid.
To explore which pre- and postoperative factors are asso-
ciated with increased charges, an adjusted multivariable lin-
ear regression model was constructed. The formula to
determine STS risk score is derived frommany preoperative
factors; however, all variables with significant associations
on univariate analysis or biological plausibility were incor-
porated in the multivariable linear regression model. Diabe-
tes mellitus, chronic obstructive pulmonary disease, and
preoperative stroke were preoperative variables signifi-
cantly associated with increased charges. This finding is
expected, because patients with these comorbidities are
known to be at greater risk for postoperative mortality after
AVR.15-17 When grouped together into a composite out-
come, the occurrence of postoperative CVA, RRT, or pneu-
monia was associated with increased charges. Because the
complication rate after AVR is relatively low, we surmise
that we would have low power to detect a significant asso-
ciation when examining any major complication indepen-
dently. Therefore, we grouped the 3 major complications
after AVR (CVA, RRT, or pneumonia) to be examined col-
lectively. The high expenses associated with RRT in the set-
ting of critical illness are already known, and we speculate
that the cost associated with this therapy may be driving the
findings in this study as well.18
In the context of recent emergence of TAVI, it is impor-
tant to rigorously examine the cost-effectiveness of these
competing therapies. AVR is known to effectively improve
survival and quality of life for patients with AS, including in
octogenarians. According to the quality of life Short Form-
36 instrument, patients aged more than 75 years undergoing
AVR had quality of life comparable to the age-matched
general population.6 Furthermore, Wu and colleagues19
prospectively evaluated a cohort of more than 4500 patients
during a 4-decade span to assess cost-effectiveness of AVR
using economic modeling.19 They applied the value of life-
years as determined by economists to calculate the
economic value of additional life afforded to the cohort
by AVR, concluding the net value of life-years gained by
AVR to be 11.2 billion dollars. In contrast with our study,
the study by Wu and colleagues preceded STS risk models,
and thus they were not able to incorporate these models in
their cost-savings analysis. Nevertheless, their study
illustrates the significant positive economic impact of tradi-
tional AVR.
The recent publication of the inoperable cohort of the
PARTNER study used an STS risk score for predicted mor-
tality of 50% (or permanent disability) as the threshold to
define the eligible study population. TAVI demonstrated
a significant survival advantage over optimal medical man-
agement, including balloon valvuloplasty, in this cohort.2
Data regarding the high risk cohort are yet unpublished;654 The Journal of Thoracic and Cardiovascular Surghowever, an STS risk score for predicted mortality of
10% was used as a cutoff to define this patient subgroup.
Thus, we compared patients with an STS risk score greater
than 10% with those with an STS risk score less than 10%.
Median index admission charges in the 19 patients with an
STS risk score greater than 10% exceeded median charges
for patients with an STS risk score less than 10% by more
than $45,000. Furthermore, according to univariate regres-
sion analysis, an STS score greater than 10% was associ-
ated with a $36,000 increase in hospital charges. Given
the current state of health care economics in the United
States, it will be imperative that the cardiovascular commu-
nity give full consideration to the cost–benefit ratio when
implementing TAVI on a broad scale.
To examine resource use for patients who die before hos-
pital discharge, we performed a charges comparison among
patients who survived to hospital discharge versus nonsur-
vivors. Median hospital charges for patients who died be-
fore hospital discharge were approximately $100,000
more than survivors. Furthermore, in the risk-adjusted mul-
tivariable linear regression model, in-hospital mortality had
an independent association with increased charges, with
a regression coefficient of 0.54. Extrapolating this coeffi-
cient from log charges to absolute charges reveals that
with all other variables being held constant, patients who
died in the hospital had on average $30,000 in excess
charges. The opposite finding was seen in a cohort of pa-
tients undergoing open thoracoabdominal aneurysm repair.
There was no difference in median charges between open
repair versus endovascular thoracic aortic aneurysm repair,
and no difference in median hospital charges between sur-
vivors versus nonsurvivors.20 That analysis included pa-
tients undergoing repair for aortic rupture, however, and
we suspect that because of different pathologies the higher
rate of early deaths in that series blunted the charges asso-
ciated with in-hospital death. It remains to be seen how
charges will compare between the open versus endovascular
approach for aortic valve disease in the future. Charges data
are not yet available for TAVI at our institution; however,
we speculate that until this technology becomes widely
available with broad competition in the marketplace,
charges associated with the device will be high.
Limitations
This study is limited by the use of hospital charges as sur-
rogate indices for cost. However, the unique medical reim-
bursement structure in the State of Maryland mitigates this
issue. The Maryland HSCRC was established by the state
legislature in 1971 to contain costs. The HSCRC determines
hospital payment rates for insurers—both private and
public—including Medicare and Medicaid within all Mary-
land hospitals. Therefore, the practice of ‘‘cost shifting’’ by
overcharging privately insured patients is absent, making
institutional charge data predictable and consistent. Theery c September 2011
Arnaoutakis et al Perioperative Managementauthors’ institution HSCRC rate for charge payment has
been costþ 1% to 3% during the study interval. Accord-
ingly, we believe this study represents a novel and accurate
assessment of charges associated with AVR. This analysis is
further limited by single-institution data. However, because
of variable payment rates across states, a multi-institutional
study involving centers in different states cannot be easily
performed.
Readmission rates and subsequent hospitalization
charges were not captured by our database. Thus, additional
study is needed to determine whether patients with in-
creased STS risk score consume greater resources after
AVR in the long-term also. A charges analysis of our insti-
tutional lung transplant recipients revealed that patients
with increased preoperative risk score (according to lung al-
location score) had increased index admission charges, but
not 1-year charges.21CONCLUSIONS
This is the first study to examine the impact of high STS
risk scores on hospital charges and resource use after AVR.
Patients in the highest STS risk quartile had increased index
admission hospital charges, greater lengths of stay, and
more complications when compared with patients in the
lower 75% of STS risk scores. There is a linear relationship
between hospital charges and STS risk score, because in-
creasing risk scores predict higher hospital charges. As
competing therapies such as percutaneous valve replace-
ment gain broader application, these results serve as
a benchmark to compare resource use across increasing
strata of STS risk scores.
The authors thank Joe DiNatale and Barbara Fleischman for du-
tiful assistance in managing the cardiac surgery database and pro-
viding STS risk score information.P
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